AI in Precision Medicine Market Size, Share & Trends Analysis Report By Component (Software, Hardware, Services), By Technology (Deep Learning, Querying Method, Natural Language Processing, Context Aware Processing), By Therapeutic Application (Oncology, Cardiology, Neurology, Respiratory, Other Applications) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

AI in Precision Medicine Market Size

The global AI in precision medicine market size was valued at USD 2.7 billion in 2025 and is projected to grow from USD 3.26 billion in 2026 to USD 14.87 billion by 2034, registering a CAGR of 20.87% during the forecast period from 2026 to 2034. North America dominated the AI in precision medicine market with a market share of 35.42% in 2025.

The AI in precision medicine market is growing rapidly as healthcare moves toward personalized treatment. AI helps doctors analyze patient data, genetics, and medical histories to design precise therapies. Tools like AI‑powered genomic platforms and predictive analytics improve drug discovery and early disease detection. Companies such as Tempus and Illumina use AI to tailor cancer treatments, while PathAI and Paige AI assist in pathology by detecting subtle patterns in tissue samples. Collaborations between tech firms and hospitals accelerate innovation, and AI models can now interpret complex multi‑omics data more efficiently. Cloud computing and automated analytics reduce manual work, speeding up decision-making. Challenges remain, including data privacy and high implementation costs, but rising awareness of personalized care and AI’s ability to improve treatment outcomes are driving wider adoption worldwide.

By Component

The software segment dominated the market, with a revenue share of 40.97%, due to widespread use of AI‑driven clinical decision support platforms that integrate genomic, imaging, and EHR data into actionable therapy insights. Advanced multi‑omics analytics engines improved rare disease diagnosis accuracy. For example, OM1’s PhenOM platform leveraged massive real‑world data to generate unique digital phenotypes for personalized treatment recommendations in 2025, boosting software demand.

The services segment is expected to grow at a CAGR of 21.36% during the forecast period, because health systems increasingly outsource AI integration and workflow optimization, helping clinics deploy and customize precision medicine models with limited in‑house IT expertise. Providers also demand ongoing model retraining and compliance support as clinical data evolves.

Request Customizationto receive a tailored report.

By Technology

The deep learning segment dominated the market, accounting for a share of 33.71% in 2025, as convolutional neural networks (CNNs) improve histopathology image analysis, enabling faster and more accurate cancer detection. Recurrent neural networks (RNNs) enhanced longitudinal patient data predictions, supporting treatment planning. Graph neural networks mapped complex proteindrug interactions for drug discovery.

The natural language processing segment is expected to grow at a CAGR of 21.95% during the forecast period, driven by regional languagespecific clinical NLP engines in Japan and India enabling the extraction of patient insights from local-language EHRs, improving personalized care. Regulatory report automation using NLP reduces manual FDA/EMA submission efforts for precision therapies. AI-driven patient consent and protocol summarization tools help clinicians quickly interpret complex trial documents.

By Therapeutic Application

The oncology segment dominated the market, accounting for a share of 31.06% in 2025. AI-enabled tumor profiling platforms integrate genomics, proteomics, and imaging for highly personalized treatment plans. Rare cancer subtype prediction models improve therapy selection and clinical trial matching. Real-world evidence platforms allow continuous monitoring of treatment outcomes. These factors collectively drive segmental market growth.

The neurology segment is projected to grow at a CAGR of 22.04% during the forecast period, as AI models analyze multi-modal brain imaging to detect early neurodegenerative changes, improving diagnosis of Alzheimer’s and Parkinson’s. Predictive algorithms for seizure and stroke risk support timely interventions. AI-driven cognitive assessment tools streamline clinical trials for neurological drugs. For example, GE Healthcare deployed deep learning platforms in US neurology clinics to enhance early detection and patient monitoring.

Speak to an Analystto discuss market opportunities.

Regional Insights

North America: Market Leadership Driven by Rich Genomic Data Ecosystem and AI‑powered Bioprinting Investments

North America AI in precision medicine market accounted for a share of 35.42% in 2025 due to the rich genomic data ecosystem from programs like the NIH All of Us Research Program, which fuels AI model training for personalized therapies, and the FDA’s clear AI/ML regulatory guidance that accelerated clinical deployments within US healthcare systems. Strategic collaborations between precision medicine providers and AI pathology innovators expanded tailored clinical trial services across the region. For example, Tempus AI, Inc. and Merck Research Laboratories partnered to accelerate AI‑driven precision medicine biomarker discovery and development in oncology. These factors are driving regional market growth.

The US market is growing due to initiatives such as Utah’s first‑in‑nation AI pilot that lets an AI system autonomously renew routine prescriptions for chronic patients, increasing access and easing clinician workload under state‑level regulatory sandboxes. The Centers for Medicare & Medicaid Services (CMS) are integrating AI into Medicare operations, highlighting federal endorsement of AI solutions that enhance efficiency and streamline healthcare service delivery. These factors collectively position the US as a leading market in North America.

Government of Canada’s major Strategic Response Fund investment in AI‑powered bioprinting and clinical research infrastructure in British Columbia, which boosts domestic innovation and commercialization capacity. A national AI‑genomics initiative (CIPHER) launched in 2026 streamlines genomic test workflows with AI, reducing diagnostic bottlenecks across provinces. Additionally, a USD 25M Digital Health Innovation Fund fuels locally anchored AI projects for cancer and neuroscience precision solutions, which, in turn, supports market growth.

Unlock Regional Insightsto access country-level data, & regional trends.

Asia Pacific: Fastest Growth Driven by Growth in AI‑Enabled Multi‑Omics Research

The Asia Pacific AI in precision medicine market is expected to register the fastest growth with a CAGR of 22.64% during the forecast period. Singapore’s AI‑enabled multi‑omics and liquid biopsy research showcased at ESMO Asia Congress 2025, which strengthens local adoption of precision oncology tools tailored to diverse APAC genetic profiles. Regional collaboration platforms like K‑CONNECT APAC 2025 united clinicians and AI experts from nine countries to advance ctDNA‑MRD diagnostics across APAC. Additionally, national genomics initiatives in Thailand and Singapore build population‑specific datasets that boost AI model relevance.

The China AI in precision medicine market grows due to highly localized drivers such as the nationwide “three‑tier AI model system” that integrates base AI models with specialized clinical and genomics fine‑tuned models, enabling more accurate multimodal diagnosis and personalized treatment planning across hospitals in 2025. The market also benefits from vast standardized medical big data pools built under national digital health initiatives, which feed deep learning systems and accelerate precision decision support innovation within Chinese clinical workflows.

GenomeIndia initiative completed whole genome sequencing for over 10,000 Indians, which supplies AI models with diverse population genetics data unique to the country. The launch of government‑supported AI healthcare centers like the TANUH CoE at IISc Bangalore drives localized AI R&D for disease detection. State‑run AI clinics in Noida integrate genetic screening with AI diagnostics to improve early detection and treatment accuracy. All these factors are expected to propel the growth in the India AI in precision medicine market.

Competitive Landscape

The AI in precision medicine market is moderately consolidated, with leading technology and healthcare companies dominating alongside specialized AI innovators. Major global players such as NVIDIA, Google (Alphabet), Microsoft, IBM, and Illumina provide foundational AI platforms, cloud computing, and genomic analytics tools that support precision medicine workflows. Niche companies like Tempus, Exscientia, PathAI, and Atomwise focus on targeted applications such as oncology therapy selection, AI‑driven drug discovery, and pathology interpretation. Competition revolves around advanced algorithm development, strategic partnerships with pharmaceutical and clinical institutions, expanded AI model capabilities, and regulatory clearances to drive adoption and global market penetration.

List of Key and Emerging Players in AI in Precision Medicine Market